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Introduction: Drugs directed toward the epidermal growth factor
receptor (EGFR), such as erlotinib (Tarceva) and gefitinib
(Iressa), are used for the treatment of patients with advanced
non-small cell lung cancer (NSCLC), including patients with
brain metastases. However, whether erlotinib actually enters into
brain metastases has not been adequately elucidated. In this
study, we investigated the accumulation of [11C]-erlotinib by
positron emission tomography (PET) combined with computed
tomography (CT) and magnetic resonance imaging (MRI).
Methods: A 32-year-old patient with NSCLC and multiple brain
metastases was treated with first-line erlotinib. EGFR mutations
were determined by analyzing a fine-needle lung tumor biopsy
taken before the treatment. A PET/CT of the brain with [11C]-
erlotinib was performed during treatment, and a MRI of the head
and a CT of the chest were performed pre- and posttreatment.
Results: The primary lung tumor displayed an erlotinib-sensitizing
exon 19 deletion in the EGFR gene, and [11C]-erlotinib PET/CT
showed accumulation in the brain metastases. Posttreatment MRI
and CT demonstrated regression of both brain metastases and
primary lung tumor.
Conclusion: Our data demonstrated that erlotinib accumulated in
brain metastases in a NSCLC patient who responded to the
treatment.
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Epidermal growth factor receptor (EGFR) represents anattractive target for treatment of many epithelial cancers
due to its role in tumorgenesis, proliferation, and prognosis.1
Tyrosine kinase inhibitors (TKI) targeting the EGFR, such as
erlotinib (Tarceva) and gefitinib (Iressa), are used for
treatment of patients with advanced non-small cell lung
cancer (NSCLC), either as first-line treatment of patients
harboring an EGFR mutation or as second-/third-line treat-
ment after platinum-based doublet chemotherapy.2,3 Dra-
matic responses to the treatment have been observed in
patients with specific EGFR mutations in the ATP-binding
domain of the EGFR protein. Most frequently, a deletion in
exon 19 and a point mutation in exon 21 (L858R) are
encountered, and both are associated with TKI sensitivity.4,5
Patients presenting with symptomatic brain metastases
and meningeal carcinomatosis have a poor prognosis, with a
median survival of 4 to 11 weeks.6 The standard treatment is
whole-brain radiotherapy, but the clinical benefit is question-
able. Intravenous chemotherapy is of limited effect due to
poor penetration of the chemotherapeutic drugs into the brain
tissue and cerebrospinal fluid.6,7 Intrathecal chemotherapy
has no clear effect in patients with solid tumors but severely
reduces quality of life due to side effects.8
Recently, several case reports have reported clinical
and objective responses of brain metastases in patients with
NSCLC after treatment with erlotinib or gefitinib.9–11 How-
ever, the ability of these drugs to accumulate in brain metas-
tases has, to our knowledge, not previously been studied.
Employing dynamic positron emission tomography
(PET)/computed tomography (CT) with [11C]-erlotinib, we
investigated whether erlotinib accumulated in brain metasta-
ses of a patient with NSCLC harboring an EGFR mutation.
CASE REPORT
A 32-year-old Chinese woman was hospitalized be-
cause of severe nausea, vomiting, headache, and multiple
convulsions. She had no medical history and had never
smoked. On admission, she had a performance status
(World Health Organization) of 4 (bedridden and com-
pletely disabled).
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The patient was diagnosed as having NSCLC (Figure
1A), multiple brain metastases, and meningeal carcinomatosis
visualized by magnetic resonance imaging (MRI) (Figure
2A). Oral administration of 150 mg erlotinib daily was chosen
as first-line treatment. No radiotherapy was given. Within 2
weeks, the patient became fully oriented and regained her
ability to walk and feed herself, although she still suffered
from nausea and impaired vision. MRI 3 weeks after the start
of treatment showed a nearly complete remission of the brain
metastases and no signs of meningeal carcinomatosis (Figure
2B compared with Figure 2A), and CT of her chest showed a
marked reduction of the mass initially observed in the lung
(Figure 1B compared with Figure 1A). New scans after 11
weeks confirmed the results.
Because of a severe grade 4 generalized papulopus-
tular rash, the dose of erlotinib was reduced to 50 mg daily
2 weeks after the start of the treatment. Continuing on this
dose, the patient remained in remission for 10.5 months
before progression of the disease, and she died 11.5
months after the start of the treatment. The patient had not
received other antineoplastic treatments nor was radiother-
apy given at any time.
The patient gave informed consent, and the study
was approved by the Ethics Committee (M-20080012,
M-20080050) and the Danish Medicines Agency (2512-
96464). The study was conducted according to the declara-
tions of Helsinki.
METHODS
PET Study
Accumulation of erlotinib in the brain metastases was
assessed 8 months after the start of erlotinib treatment by
PET/CT using [11C]-erlotinib, a novel PET tracer developed
by our group.12 Before the PET/CT study, the patient did not
take the drug for 7 days, thereby minimizing competition
between the binding of unlabeled and labeled erlotinib to
receptor sites on the tumor cells.
Imaging was performed using an advanced PET/CT
imaging system, Siemens Biograph 64 (Siemens AG, Erlan-
gen, Germany) (Memon et al., unpublished data, 2011). A
low-dose CT acquisition of the head and thorax was per-
formed before administration of the tracer for attenuation
correction and anatomical references.
[11C]-Erlotinib (433 MBq) was administered intrave-
nously, followed by dynamic PET recording of the brain for
60 minutes using list-mode acquisition. Images were recon-
structed by an attenuation-weighted ordered-subsets expecta-
tion maximization algorithm (3 iterations, 21 subsets) fol-
lowed by a postreconstruction smoothing Gaussian filter
(3-mm full width at half maximum). PET images were
coregistered with gadolinium-enhanced T1-weighted MR
images.
Mutation Analysis
A fine-needle aspiration biopsy of the lung tumor tissue
was removed 2 weeks before the start of treatment. Mutation
analysis of exon 19 of the EGFR gene by the Sanger sequenc-
ing technique was performed.
FIGURE 1. Computed tomography of the
chest before (A) and 3 weeks after start of
treatment with erlotinib (B) of a 32-year-old
woman diagnosed with non-small cell lung
cancer with brain metastases who harbored
an exon 19 mutation. Arrows indicate the
tumor sites.
FIGURE 2. Two axial magnetic resonance imaging of the
brain before (A) and 3 weeks after start of treatment (B) of a
32-year-old woman diagnosed with non-small cell lung can-
cer and brain metastases harboring an exon 19 mutation.
Arrows indicate positions of brain metastases.
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RESULTS
PET Study
The PET images showed increased 11C activity in brain
foci corresponding to MRI foci, with increased contrast
accumulation indicating tumor nodules (Figure 3). Uptake in
muscle tissue and meninges was also observed. The 11C
activity in the cerebral cortex was very low, making delinea-
tion of tumor tissue from normal brain tissue easy (Figure 3);
tumor-to-cortex ratios up to 10:1 were observed.
Mutation Analysis
The mutation analysis revealed an exon 19 deletion
(delL747-P753insS) in the EGFR gene.
DISCUSSION
Using 11C-erlotinib PET/CT images combined with
MR images, we demonstrated erlotinib accumulation in met-
astatic lesions in the brain of a patient with NSCLC harboring
a deletion in exon 19 of the EGFR gene. Moreover, treatment
with erlotinib as monotherapy was followed by a reduction in
size of both the brain metastases and the primary lung tumor.
Dynamic PET recording showed continued 11C-erlo-
tinib accumulation during the 60-minute study period, indi-
cating binding to receptors on the tumor cells. Interestingly,
no accumulation was seen elsewhere in the cortex.
The finding of erlotinib accumulation in brain metastases
is in accord with the dramatic response of this drug on the brain
metastases both in our patient and in previously described
patients.9,11 There is increasing evidence that most patients with
partial or complete responses to erlotinib or gefitinib have a
somatic mutation in the EGFR possibly because the binding
affinity of erlotinib to a mutated receptor is much higher than for
a nonmutated receptor.13 This could explain the clinical obser-
vation that a dose as low as one-third of the recommended dosewas
sufficient to maintain remission in our patient and other patients.14
A small Korean study (N  23) reported the use of a
TKI targeting the EGFR in the first-line treatment of lung
cancer patients with brain metastases.15 This study, which
included only never-smokers (known to have a high proba-
bility of harboring EGFR mutations) with nonsymptomatic
brain metastasis, demonstrated a MRI-detected intracranial
response rate of 73.9%, according to RECIST.
In conclusion, our study showed a beneficial effect of
erlotinib in a patient with highly symptomatic brain metastases
and demonstrated erlotinib accumulation in the metastatic lesions.
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FIGURE 3. Gadolinium-enhanced T1-weighted magnetic resonance imaging (MRI) (A) coregistered with [11C]-erlotinib posi-
tron emission tomography (PET) (sum image, 5–60 minutes after tracer administration) (B) of a 32-year-old woman diag-
nosed with non-small cell lung cancer and brain metastases harboring an exon 19 mutation. The selected MRI image shows
two metastatic lesions in the cerebellum. The [11C]-erlotinib PET image shows abnormal accumulation in focal areas corre-
sponding to the two lesions on the MRI scan. Note the absence of [11C]-erlotinib accumulation in normal brain tissue.
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